Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraoperative epirubicin after curative resection for hepatocellular carcinoma
ACTRN12611000471987Phase 4Not yet recruiting
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Jun 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of epirubicin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Eastern Hepatobiliary Surgery Hospital. Primary endpoints: Time to recurrence and Overall survival. Planned start Jun 2011; status: not yet recruiting.
02
Drugs
epirubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ACTRN12611000471987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000471987.